# Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

> **NCT00542828** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **BIOLOGICAL:** Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)

## Key facts

- **NCT ID:** NCT00542828
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-05
- **Final completion:** 2009-07
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study terminated due to slow enrollment.
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542828, "Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00542828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*